

Tadao Akizawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5339436/publications.pdf>

Version: 2024-02-01

77
papers

3,956
citations

147801

31
h-index

118850

62
g-index

80
all docs

80
docs citations

80
times ranked

2814
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. <i>Kidney International</i> , 2005, 67, 1179-1187.	5.2	640
2	Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2004, 44, 94-111.	1.9	600
3	Clinical Practice Guideline for the Management of Chronic Kidney Disease—Mineral and Bone Disorder. <i>Therapeutic Apheresis and Dialysis</i> , 2013, 17, 247-288.	0.9	305
4	2008 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2010, 14, 240-275.	0.9	211
5	Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1628-1639.	6.1	133
6	Therapeutic Apheresis for Septic Patients with Organ Dysfunction: Hemoperfusion using a Polymyxin B Immobilized Column. <i>Artificial Organs</i> , 1998, 22, 1038-1044.	1.9	94
7	Cardiovascular events and death in Japanese patients with chronic kidney disease. <i>Kidney International</i> , 2017, 91, 227-234.	5.2	93
8	Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. <i>American Journal of Nephrology</i> , 2017, 45, 127-135.	3.1	85
9	Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 115-125.	0.9	81
10	Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1155-1165.	4.5	80
11	Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. <i>American Journal of Kidney Diseases</i> , 2004, 44, 27-33.	1.9	78
12	Effects of Molidustat in the Treatment of Anemia in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 28-39.	4.5	78
13	Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 446-456.	1.6	68
14	Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3643-3653.	0.7	65
15	Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. <i>Kidney International</i> , 2018, 94, 818-825.	5.2	65
16	A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. <i>American Journal of Nephrology</i> , 2019, 49, 165-174.	3.1	62
17	Naturally Occurring Higher Hemoglobin Concentration Does Not Increase Mortality among Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 358-365.	6.1	58
18	Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. <i>Biochemical and Biophysical Research Communications</i> , 2007, 362, 11-16.	2.1	54

#	ARTICLE	IF	CITATIONS
19	<scp>COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic Apheresis and Dialysis, 2020, 24, 361-365.	0.9	53
20	Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies. Therapeutic Apheresis and Dialysis, 2020, 24, 628-641.	0.9	51
21	A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS ONE, 2018, 13, e0195316.	2.5	50
22	Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. American Journal of Kidney Diseases, 2004, 44, 27-33.	1.9	48
23	NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD. Kidney International Reports, 2018, 3, 73-80.	0.8	48
24	A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis. Nephron, 2020, 144, 372-382.	1.8	48
25	PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Scientific Reports, 2016, 6, 19612.	3.3	47
26	Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. American Journal of Nephrology, 2019, 49, 271-280.	3.1	40
27	Burden of Anemia in Chronic Kidney Disease Patients in Japan: A Literature Review. Therapeutic Apheresis and Dialysis, 2018, 22, 444-456.	0.9	39
28	The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis. British Journal of Clinical Pharmacology, 2004, 57, 726-734.	2.4	36
29	Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial. Nephron, 2019, 143, 77-85.	1.8	36
30	A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Therapeutic Apheresis and Dialysis, 2020, 24, 108-114.	0.9	36
31	Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD. Kidney International Reports, 2021, 6, 1810-1828.	0.8	35
32	Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort study. Renal Replacement Therapy, 2021, 7, 59.	0.7	34
33	Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism. Therapeutic Apheresis and Dialysis, 2008, 12, 117-125.	0.9	29
34	Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. American Journal of Nephrology, 2021, 52, 871-883.	3.1	24
35	Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open, 2019, 9, e026704.	1.9	22
36	A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study. Kidney International Reports, 2021, 6, 1840-1849.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis. <i>Kidney International Reports</i> , 2021, 6, 2604-2616.	0.8	22
38	Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. <i>American Journal of Nephrology</i> , 2021, 52, 884-893.	3.1	22
39	Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 248-257.	0.9	21
40	A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study. <i>Kidney Diseases (Basel, Switzerland)</i> , 2021, 7, 494-502.	2.5	21
41	Impacts of Recombinant Human Erythropoietin Treatment During Predialysis Periods on the Progression of Chronic Kidney Disease in a Large-scale Cohort Study (<sc>C</sc>â€œ<sc>JET</sc>) Tj ETQq0.0 0.784334 rgBT	0.784334	14
42	Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. <i>PLoS ONE</i> , 2018, 13, e0204896.	2.5	18
43	Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. <i>BMJ Open</i> , 2019, 9, e026602.	1.9	18
44	Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis. <i>Scientific Reports</i> , 2019, 9, 6410.	3.3	16
45	Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. <i>Kidney International Supplements</i> , 2013, 3, 436-441.	14.2	15
46	Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study. <i>Clinical Drug Investigation</i> , 2018, 38, 945-954.	2.2	15
47	Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. <i>Clinical Therapeutics</i> , 2018, 40, 2099-2111.	2.5	14
48	Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 575-585.	0.9	13
49	Two long-term phase 3 studies of enarodustat (<sc>JTZ</sc>â€951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: <sc>SYMPHONY NDâ€Long</sc> and <sc>HDâ€Long</sc> studies. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 345-356.	0.9	13
50	Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japanâ€”A Phase 2 Randomized Trial. <i>Kidney International Reports</i> , 2022, 7, 177-188.	0.8	13
51	Pharmacokinetics of evocalcet in secondary hyperparathyroidism patients receiving hemodialysis: first-in-patient clinical trial in Japan. <i>Clinical Pharmacology: Advances and Applications</i> , 2018, Volume 10, 101-111.	1.2	12
52	Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 258-267.	1.6	12
53	Effectiveness of <sc>SARSâ€CoV</sc>â€2 vaccines on hemodialysis patients in Japan: A nationwide cohort study. <i>Therapeutic Apheresis and Dialysis</i> , 2023, 27, 19-23.	0.9	12
54	The Effects and Pharmacokinetics of rhG-CSF in Patients with Chronic Renal Failure. <i>Artificial Organs</i> , 1995, 19, 1251-1257.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 739-748.	1.6	11
56	Plasma Exchange for Thrombocytopenia in Antiphospholipid Syndrome: A Case Report. <i>Therapeutic Apheresis and Dialysis</i> , 1998, 2, 157-159.	0.6	10
57	Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 2371-2380.	0.8	10
58	Management of secondary hyperparathyroidism of dialysis patients. <i>Nephrology</i> , 2003, 8, S53-S57.	1.6	9
59	Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, , .	0.9	8
60	Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). <i>Clinical and Experimental Nephrology</i> , 2016, 20, 71-76.	1.6	7
61	Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single-arm, phase 3 study. <i>Therapeutic Apheresis and Dialysis</i> , 2021, 25, 917-925.	0.9	7
62	Treatment of anemia associated with chronic kidney disease with the <scp>HIF</scp> prolyl hydroxylase inhibitor enarodustat: A review of the evidence. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 679-693.	0.9	7
63	Evaluation of Å ² â€Microglobulin Removal with Highâ€Performance Hemodiafiltration. <i>Artificial Organs</i> , 1988, 12, 11-15.	1.9	6
64	Membranous glomerulonephropathy in a patient with bullous pemphigoid. <i>CEN Case Reports</i> , 2017, 6, 50-54.	0.9	4
65	Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients. <i>Kidney International Reports</i> , 2021, 6, 2830-2839.	0.8	4
66	SP334IRON REGULATION BY MOLIDUSTAT, BAY 85-3934, A DAILY ORAL HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITOR IN PATIENTS WITH CHRONIC KIDNEY DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i457-i457.	0.7	3
67	Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS). <i>BMJ Open</i> , 2019, 9, e031476.	1.9	3
68	Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin. <i>Kidney International Reports</i> , 2022, 7, 763-775.	0.8	3
69	Safety of daprodustat in patients with anemia of chronic kidney disease: A pooled analysis of phase 3 studies in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2022, , .	0.9	3
70	Pharmacokinetic/pharmacodynamic modeling of roxadustat's effect on LDL cholesterol in patients in Japan with dialysis-dependent chronic kidney disease and anemia. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 46, 100461.	2.2	3
71	<p>Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2020, Volume 13, 97-106.	1.8	2
72	Myocardial <scp>SPECT</scp> Images in Incident Hemodialysis Patients Without Ischemic Heart Disease. <i>Therapeutic Apheresis and Dialysis</i> , 2015, 19, 575-581.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Therapeutic Apheresis and Therapeutic Plasmapheresis: The Relationship to the Annual Meeting of the Japanese Society for Apheresis. Therapeutic Apheresis and Dialysis, 1997, 1, 307-307.	0.6	0
74	Clinical application of FR-860 to hemodialysis: Multicenter cooperative study in Japan.. Journal of Japanese Society for Dialysis Therapy, 1991, 24, 507-514.	0.0	0
75	Clinical effect of L-threo-3, 4-dihydroxyphenylserine (L-threo-DOPS) on orthostatic hypotension in hemodialysis patients. A placebocontrolled double-blind study.. Nihon Toseki Igakkai Zasshi, 1997, 30, 941-959.	0.1	0
76	Appreciation for the contribution of the Japanese Society for Dialysis Therapy to development of Therapeutic Apheresis and Dialysis. Therapeutic Apheresis and Dialysis, 2021, 25, 726-726.	0.9	0
77	Dose-Response of Tenapanor in Patients with Hyperphosphatemia Undergoing Hemodialysis in Japan- A Phase 2 Randomized Trial. Kidney International Reports, 2022, , .	0.8	0